An observational study in Salivary Gland Cancer and Salivary Gland Neoplasms, sponsored by Clinical Center of Vojvodina. Completed at 1 site in Serbia. Per ClinicalTrials.gov, last updated 2022-05-25.
Sponsored by Clinical Center of Vojvodina · Observational
Salivary gland malignancies is very heterogenous group of tumors regarding tumor histology and localization. The aim of this study is to assess main clinical and pathological parameters related to patients survival
The retrospective study enrolled medical charts of the patients treated due to salivaly gland cancers in the Clinic for maxillofacial surgery at Clinical center of Vojvodina in the period of 1. January 1996. to 31. December 2021. Patients demographics, type of the tumor, localization, TNM status and patohystological parameters were evaluated for patients survival and disease free periods
242 studies on the registry are indexed under Salivary Gland Neoplasms; 29 are open to participants now.
This study's enrollment of 250 is above the median of 130 across 43 observational studies indexed under Salivary Gland Neoplasms.
Browse Salivary Gland Neoplasms studies →Clinical Center of Vojvodina is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients treated due to SGC in the Clinic for maxillofacial surgery at Clinical center of Vojvodina
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients with salivary gland treted in the Clinic for maxillofacial surgery
Exclusion Criteria:
Incomplete medical data Patients with tumord of salivary gland Patients with recurrent of salivary glands sent from other clinics
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients treated due to SGC without local recurrence or metastases
Procedure: Surgical intervention with or without postoperative adjuvant therapy
Patient with relapse of SGC, metastases or died due to SGC
Procedure: Surgical intervention with or without postoperative adjuvant therapy
Surgical intervention with or without postoperative adjuvant therapy
Patients survival
Survival of patients treated due to SGC during observation period of minimum 2 years
Time frame: Through study completion, an average of 1 year
Plan to share: No
No publications or documents are linked to this record.
Ran from Jan 2022 to primary completion in Mar 2022, 2 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Clinical Center of Vojvodina